AusBiotech is calling for companies to present at Australia’s premier life science investment event: Australia Biotech and Invest Partnering 2019.
This event is run for industry, by industry, and provides investment-seeking companies an opportunity to take centre-stage and make meaningful connections with the investment community.
The full-day programme features four keynote speakers, and up to 30 company presentations showcasing the potential of life science companies to an anticipated 400 investors and global pharmaceutical companies. Complimentary entry is offered to all investors.
This year will see the event being held at the same time as AusBiotech 2019, AusBiotech’s national conference. This year all registered investors and delegates are able to access to AusBiotech’s business matching programme to pre-schedule one-on-one meetings and network with up to 1,500 attendees from both conferences. Special packages have also been developed to attend both conferences, saving delegates $1,000.
This year’s programme includes four keynote speakers, including an ASX market update, a big pharma perspective, an investor’s insights, and a spotlight briefing on valuation.
Dr Niels Emmerich, Vice President, Global Head Search & Evaluation will deliver the big pharma perspective, considering where the sector is now since the launch of the Biomedical Translation Fund, new ways that pharma is engaging with the venture capital sector, and how models for external innovation through partnerships has enabled the development of emerging technologies. Niels joined AbbVie in 2011, and has been involved in acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CALIBR, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC, Turnstone, X-Chem) and venture investments.
Highly-recognised Canadian life sciences leader with broad global experience, Ms Karimah Es Sabar, Chief Executive Officer & Partner, Quark Venture LP, Canada, has had a successful career spanning multi-national pharmaceutical, biotechnology companies, start-up, not-for-profit organisations and venture investment firm. Karimah will share her knowledge on the Canadian biotech market, VC landscape and development of Quark Venture's life sciences fund with China’s GF Securities a leading investment bank, which is among the largest of its kind in the country. The fund is diversified to invest globally in disruptive pre-clinical platforms, clinical stage companies, IPOs and publicly traded companies in therapeutics, vaccines, medical devices, health IT, health AI and novel emerging convergent technologies.
Dr Patrik Frei, CEO, Venture Valuation will speak on the valuation of biotech companies, assets, and products for financing or licensing, what is important when raising money/speaking to investors, and financing/licensing trends.
In addition, Venture Valuation are also running a full-day pre-conference workshop on Tuesday 29 October for delegates to learn how to calculate and determine the right assumption for any therapeutic product (pre-clinical, clinical or on the market) to structure a suitable licensing deal, and to understand how to assess a biotech company for financing rounds and M&A. Register here for the pre-conference workshop.
Australia Biotech Invest & Partnering will be held on Friday 1 November at the Melbourne Convention Exhibition Centre. Australia Biotech and Invest Partnering 2019 and AusBiotech 2019 are proudly sponsored by the Victorian Government.
Life sciences companies are invited to apply for their eight-minute company presentation here.
Investors and interested delegates can register their interest here.